EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
I haven't even had my first cup of coffee yet this morning and already the trash-talking has begun. Anyhow, this BG-12 announcement is good news! They don't actually say that BG-12 is now going on to Phase III trials, but I assume it will. Is it jumping the gun to move it to phase III?
Why not. Biogen has three drugs at Phase II - rituxan (rituximab), daclizumab and BG-12 (all RR according to their website). I'm not sure when the others entered Phase II but results should be known, I would guess, in the not too distant future. I wonder if Biogen might wait to see the results of all three before deciding which one / two pursue (given that they also have Avonex and Tysabri could make a come back). Daclizumab looked very effective in the early trials. It wouldn't seem commercially sensible to have so many drugs for the same condition - unless they want us to combine.
I suppose if these new drugs prove to be effective in only subsets of MS patients, then it would make sense to have as many drugs as possible in the hope that one of the company's drugs will work for every MS patient. I'm sceptical that one of these 3 drugs would work for everybody though.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
